Success Metrics

Clinical Success Rate
91.7%

Based on 22 completed trials

Completion Rate
92%(22/24)
Active Trials
0(0%)
Results Posted
50%(11 trials)
Terminated
2(7%)

Phase Distribution

Ph phase_2
4
15%
Ph phase_3
7
26%
Ph phase_4
6
22%
Ph phase_1
3
11%
Ph not_applicable
5
19%

Phase Distribution

3

Early Stage

4

Mid Stage

13

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
3(12.0%)
Phase 2Efficacy & side effects
4(16.0%)
Phase 3Large-scale testing
7(28.0%)
Phase 4Post-market surveillance
6(24.0%)
N/ANon-phased studies
5(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.7%

22 of 24 finished

Non-Completion Rate

8.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

27

all time

Status Distribution
Completed(22)
Terminated(2)
Other(3)

Detailed Status

Completed22
unknown3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
27
Active
0
Success Rate
91.7%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (12.0%)
Phase 24 (16.0%)
Phase 37 (28.0%)
Phase 46 (24.0%)
N/A5 (20.0%)

Trials by Status

completed2281%
unknown311%
terminated27%

Recent Activity

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT03136705Phase 1

Healthy Combine Study

Completed
NCT02209636Phase 4

Phosphate Lowering in CKD Trial

Completed
NCT02258074Phase 2

The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE

Completed
NCT03451019Phase 4

Different Effects of Non-calcium Phosphate Binders on Serum Calcium

Completed
NCT00557323

Long-term Effect of Lanthanum Carbonate on Bone

Completed
NCT00151918Phase 3

Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease

Completed
NCT00160121Phase 4

Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease

Completed
NCT01130831

Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy

Completed
NCT00150540Phase 3

A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.

Completed
NCT00875017Phase 1

Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers

Completed
NCT01696279Phase 2

A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis

Completed
NCT01128179Phase 2

Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD

Completed
NCT00150566Phase 3

Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood

Completed
NCT00151931Phase 3

Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis

Completed
NCT00234702Phase 2

Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease

Completed
NCT00452478Phase 4

Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5

Terminated
NCT02237534Phase 4

Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia

Unknown
NCT03346369Phase 3

Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis

Unknown
NCT01578200Phase 3

Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study

Completed
NCT01581996Not Applicable

Fosrenol and Phosphorus Balance - Lanthanum Carbonate

Completed

Drug Details

Intervention Type
DRUG
Total Trials
27